Concepedia

Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial

Günter U. Höglinger, Irene Litvan, Nuno Mendonça, Deli Wang, Hui Zheng, Beatrice Rendenbach‐Mueller, Hoi‐Kei Lon, Ziyi Jin, Nahome Fisseha, Kumar Budur,

The Lancet Neurology · 2021 · 138 citations · 28 references

DOIFull text

Open access

Concepts

References

28

A clinical rating scale for progressive supranuclear palsy

Lawrence I. Golbe, Pamela Ohman‐Strickland · Brain · 2007 · 613 citations · Full text

, , +12

Anti-Tau Antibodies that Block Tau Aggregate Seeding In Vitro Markedly Decrease Pathology and Improve Cognition In Vivo

Kiran Yanamandra, Najla Kfoury, Hong Jiang et al. · Neuron · 2013 · 582 citations · Full text

, , +16

Prevalence, characteristics, and survival of frontotemporal lobar degeneration syndromes

Ian Coyle‐Gilchrist, Katrina M. Dick, Karalyn Patterson et al. · Neurology · 2016 · 540 citations · Full text

, , +16

Immunotherapy Targeting Pathological Tau Conformers in a Tangle Mouse Model Reduces Brain Pathology with Associated Functional Improvements

Ayodeji A. Asuni, Allal Boutajangout, David Quartermain et al. · Journal of Neuroscience · 2007 · 506 citations · Full text

, , +17

Clinical outcomes of progressive supranuclear palsy and multiple system atrophy

S. S. O'Sullivan, Luke A. Massey, David R. Williams et al. · Brain · 2008 · 420 citations · Full text

, , +11